Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 2Gastrointestinal 1

Conditions

Breast Neoplasms 175Colorectal Neoplasms 153Rectal Neoplasms 121Stomach Neoplasms 112Pancreatic Neoplasms 60Neoplasm Metastasis 60Colonic Neoplasms 42Triple Negative Breast Neoplasms 34Neoplasms 29Esophageal Neoplasms 28Cholangiocarcinoma 17Biliary Tract Neoplasms 17Nasopharyngeal Carcinoma 16Gallbladder Neoplasms 16Carcinoma, Hepatocellular 16Adenocarcinoma 16Locally Advanced Rectal Cancer 15Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 10Esophageal Squamous Cell Carcinoma 10Brain Neoplasms 10Bile Duct Neoplasms 10Adenocarcinoma Of Esophagus 10Liver Neoplasms 9Gastrointestinal Neoplasms 9Breast Neoplasms, Male 9Neuroendocrine Tumors 7Colorectal Cancer Metastatic 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × Capecitabine × Clear all
NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
150 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT02007148 2019-02-27

MICADO

International Group of Endovascular Oncology

Phase 2 Unknown
51 enrolled

Neoplasm Metastasis, Recurrence

NCT01364493 2017-05-09

A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Peking University

Phase 2 Completed
51 enrolled
Gastrointestinal

Neoplasm Metastasis, Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡